BioCentury
ARTICLE | Clinical News

N91115: Phase II started

December 14, 2015 8:00 AM UTC

Nivalis began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 200 and 400 mg oral N91115 twice daily with oral Orkambi lumacaftor/ivacaftor in 135 CF patients who have 2 copies of...